115 matching studies

Sponsor Condition of Interest
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Carna Biosciences, Inc. B-cell Malignancy Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Waldenstrom Macroglobulinemia Mantle Cell Lymphoma
This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy. expand

This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

Type: Interventional

Start Date: Aug 2023

open study

Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patient1
Surgimab Colorectal Neoplasms
The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard "white light" visualization during surgical resections of colorectal cancer. expand

The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard "white light" visualization during surgical resections of colorectal cancer.

Type: Interventional

Start Date: Jun 2019

open study